Lung Cancer - Non Small Cell SquamousLungCast2NCT07127263
Comparison of Longer-term (5 Year+) Outcomes (Survival) of Smokers, Ex-smokers, Never Smoker and Quitters
An observational study of Lung Cancer - Non Small Cell Squamous, run by Hywel Dda Health Board at 1 site in United Kingdom.
Trial summary
Between 2010-2020, the LungCAst observational study followed 3700 patients newly diagnosed with lung cancer across 33 hospitals in Wales and England for 2 years to see if smoking status at time of diagnosis predicted survival rate. This research was sponsored and led by Hywel Dda University Health Board (HDUHB). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer - Non Small Cell Squamous
- How many people
- 525 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 5 Sep 2024to 30 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients from the Hywel Dda University Health Board's (HDUHB) site that participated in the original LungCast study.
Who may be able to join
- All patients from the Hywel Dda University Health Board's(HDUHB) site that participated in the original LungCast study
Who cannot join
- Individuals that did not participate in the original LungCast study in the HDUHB site.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Hywel Dda University Health Board
Carmarthen, Carmarthenshire, SA31 3BB
About this study
Official title: Comparison of Longer Term Outcomes Following the LungCast "Smoking Cessation in Lung Cancer Study". Revisiting the Original LungCast Research Cohort to Look at Longer-term Outcomes (5+ Years) in Newly Diagnosed Lung Cancer, Within Hywel Dda University Health Board Participants Only, Who Were Smokers, Ex-smokers, Never Smoker and Quitters.
Between 2010-2020, the LungCAst observational study followed 3700 patients newly diagnosed with lung cancer across 33 hospitals in Wales and England for 2 years to see if smoking status at time of diagnosis predicted survival rate. This research was sponsored and led by Hywel Dda University Health Board (HDUHB).
This new study examines the health records, (of only the HDUHB participants included in the original LungCAst study), over a longer period of time to see if the benefits of stopping smoking at point of diagnosis with lung cancer continues over a longer period of time (5 years+).
Read the detailed description
A study into longer-term outcomes from the LUNGCAST study: comparing survival and healthcare utilisation according to smoking status in people with lung cancer, beyond 2 years. By obtaining Hospital Episode Statistics (HES) extract from the Welsh Patient Administration System (WPAS) and Welsh Clinical Portal (WCP) the investigators can retrospectively follow the cohort participants over time and analyse health care utilisation activity, using univariate and multivariate analysis on the effect of smoking status on survival. The Kaplan-Meier method, will be used to estimate the probability of survival over time.
- Conditions
- Lung Cancer - Non Small Cell Squamous
- Keywords
- Smoking cessation, Lung cancer, Survival, Tobacco
- Medical subject headings
- Smoking Cessation, Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Diagnosed Lung Cancer | Patients diagnosed with Lung Cancer, with smoking status recorded at time of diagnosis. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of longer-term (5 year+) outcomes (survival) of smokers, ex-smokers and never smokers diagnosed with lung cancer between 2010 and 2020
Following participants with lung cancer over a 5 year period, by reviewing ongoing healthcare activity via HES extraction and applying the Kaplan-Meier method, to evaluate if smoking status at diagnosis predicts better survival rates over a longer period of time. Univariate and multivariate analysis on the effect of smoking status on survival will also be applied.
Measured: From date of diagnosis (of having lung cancer) for 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2025
- Study start5 Sep 2024
- Primary completion4 Feb 2025
- Study completion30 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Cancer - Non Small Cell SquamousStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 525 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hywel Dda Health Board
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07127263
- Sponsor's protocol ID
- IRAS 339817
- Acronym
- LungCast2
- Status last verified
- Apr 2025
- First submitted
- 7 May 2025
- Last updated
- 17 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Longer Term Outcomes Following the LungCast "Smoking Cessation in Lung Cancer Study". Revisiting the Original LungCast Research Cohort to Look at Longer-term Outcomes (5+ Years) in Newly Diagnosed Lung Cancer, Within Hywel Dda University Health Board Participants Only, Who Were Smokers, Ex-smokers, Never Smoker and Quitters.
- ClinicalTrials.gov ID
- NCT07127263
- Acronym / sponsor ID
- LungCast2 / IRAS 339817
- Conditions
- Lung Cancer - Non Small Cell Squamous
- Keywords
- Smoking cessation, Lung cancer, Survival, Tobacco
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 525 participants (actual)
- Lead sponsor
- Hywel Dda Health BoardUniversity, hospital or other
- Study start
- 5 Sep 2024 (actual)
- Primary completion
- 4 Feb 2025 (actual)
- Study completion
- 30 May 2025 (actual)
- First posted
- 17 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Between 2010-2020, the LungCAst observational study followed 3700 patients newly diagnosed with lung cancer across 33 hospitals in Wales and England for 2 years to see if smoking status at time of diagnosis predicted survival rate. This research was sponsored and led by Hywel Dda University Health Board (HDUHB).
This new study examines the health records, (of only the HDUHB participants included in the original LungCAst study), over a longer period of time to see if the benefits of stopping smoking at point of diagnosis with lung cancer continues over a longer period of time (5 years+).
Detailed description
A study into longer-term outcomes from the LUNGCAST study: comparing survival and healthcare utilisation according to smoking status in people with lung cancer, beyond 2 years. By obtaining Hospital Episode Statistics (HES) extract from the Welsh Patient Administration System (WPAS) and Welsh Clinical Portal (WCP) the investigators can retrospectively follow the cohort participants over time and analyse health care utilisation activity, using univariate and multivariate analysis on the effect of smoking status on survival. The Kaplan-Meier method, will be used to estimate the probability of survival over time.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Diagnosed Lung Cancer | – | –Patients diagnosed with Lung Cancer, with smoking status recorded at time of diagnosis. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients from the Hywel Dda University Health Board's (HDUHB) site that participated in the original LungCast study.
Key inclusion criteria (1 listed)
- All patients from the Hywel Dda University Health Board's(HDUHB) site that participated in the original LungCast study
Key exclusion criteria (1 listed)
- Individuals that did not participate in the original LungCast study in the HDUHB site.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Comparison of longer-term (5 year+) outcomes (survival) of smokers, ex-smokers and never smokers diagnosed with lung cancer between 2010 and 2020
Time frame: From date of diagnosis (of having lung cancer) for 5 years
Following participants with lung cancer over a 5 year period, by reviewing ongoing healthcare activity via HES extraction and applying the Kaplan-Meier method, to evaluate if smoking status at diagnosis predicts better survival rates over a longer period of time. Univariate and multivariate analysis on the effect of smoking status on survival will also be applied.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Lung Cancer - Non Small Cell Squamous
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Not yet recruitingPhase 2
Phase II Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cell Lung Cancer
Patients With Locally Advanced or Metastatic Non-Squamous NSCLC Requiring First-Line Treatment and no Driver Gene Alterations Confirmed by Histology or Cytology
Active, not recruitingPhase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Non-small Cell Lung Cancer
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer - Non Small Cell Squamous, run by Hywel Dda Health Board at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of longer-term (5 year+) outcomes (survival) of smokers, ex-smokers and never smokers diagnosed with lung cancer between 2010 and 2020 (time frame: From date of diagnosis (of having lung cancer) for 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2025.